Siegfried: Revocation of FDA warning letter
Siegfried announces comprehensive solution for the Hameln facility's regulatory issues
In 2012, the FDA issued a warning letter to Hameln Pharma. Siegfried provided support to the company in compliance matters prior to the acquisition. Now, following revocation of the warning letter, the path has been cleared for the Hameln Pharma facility to be immediately and fully integrated into the Siegfried Group’s worldwide compliance system. The warning letter revocation also permits an American customer to import its product to the USA. The German regulatory authorities have recently confirmed renewal of Hameln’s GMP certificate required in regular intervals.
Siegfried CEO Rudolf Hanko: “This is an announcement which our American customers, especially, have been waiting for. Revocation of the warning letter is the result of joint efforts. It represents a significant step in Hameln’s ongoing integration process into the Siegfried Group.
Most read news
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.